The Next Frontier of Medicines for Cardiometabolic Diseases

Cardiometabolic disease remains the largest cause of morbidity and mortality worldwide. Marea is harnessing large-scale human genetic data and adipocyte biology to develop first-in-class treatments that target critical and unaddressed drivers of cardiometabolic diseases.

Creating a premier cardiometabolic disease company

Led by a renowned team of scientific founders, clinical advisors and biopharma executives, we aim to leverage the latest advances in human genetic data to identify, create and develop novel therapies to make a significant impact for the millions of people living with cardiometabolic diseases. These are patients who need new types of medicines because they remain at high risk despite the best currently available therapies.

See Our Leadership

Science & Approach

New mechanisms are urgently needed to treat cardiometabolic diseases at their source. Existing therapies are primarily focused on managing symptoms with few approved treatment approaches targeting the underlying biology of cardiometabolic diseases.

Marea is a clinical-stage company with a growing pipeline of first-in-class therapies to address genetically-validated cardiometabolic disease targets.

Our therapies have the potential to complement existing therapies and serve as transformative treatment options for significant patient populations living with cardiometabolic diseases.

 

Our Pipeline

Our Team

Marea is led by a dynamic team of scientists and company builders with deep know-how and experience in cardiometabolic diseases, human genetics and adipocyte biology.

Leadership

View Bio

Josh Lehrer, M.D., M.Phil., FACC
Chief Executive Officer, Marea

Ethan Weiss, M.D.
Chief Scientific Officer

Mark Joing, MBA
Chief Development Operations Officer

Founders

Board of Directors

Ted Love, M.D.
Chairman, former president and chief executive officer of Global Blood Therapeutics (acquired by Pfizer) and chairman, Biotechnology Innovation Organization (BIO)

Jung Choi, MBA
Entrepreneur in residence, Third Rock Ventures

Join us to develop the next generation of treatments for cardiometabolic diseases.

Marea is a fast-growing company looking for extraordinary individuals to join our team who want to make a difference in the lives of millions of people living with cardiometabolic diseases.

Contact

Marea Therapeutics ©2024

Charles Homcy, M.D.
Partner Emeritus, Third Rock Ventures

Sir Stephen O’Rahilly, M.D., FRS Professor of Clinical Biochemistry and Medicine, University of Cambridge

Joshua Rabinowitz, M.D., Ph.D. Professor of Chemistry & Integrative Genomics, Princeton University

View BioView BioView BioView BioView BioView Bio

Josh Lehrer, M.D., M.Phil., FACC
Chief Executive Officer, Marea

(415) 766-3610

info@mareatx.com

135 Mississippi St
San Francisco, CA 94107

SciencePipelineTeamNewsCareersTerms & ConditionsPrivacy Policy

MAR001   (ANGPTL4 mAb)

Future Pipeline

Our lead program, MAR001, is a monoclonal antibody that targets ANGPTL4, a protein that is highly expressed in adipose tissue. By inhibiting ANGPTL4 and thereby augmenting lipoprotein lipase (LPL) activity, MAR001 aims to lower remnant cholesterol and improve adipose tissue function. Human genetic data has identified ANGPTL4 as a highly promising therapeutic target because loss of function alleles lead to remnant cholesterol clearance, improved adipose distribution, better insulin sensitivity, lower triglyceride levels, and protection from cardiovascular disease and type 2 diabetes.

Preclinical models with MAR001 demonstrated reduction in triglycerides, remnant cholesterol and ectopic fat, and improved insulin sensitivity. MAR001 has demonstrated strong Phase 1 results and is in Phase 2 clinical development for adults with metabolic dysfunction.

Marea is advancing multiple undisclosed discovery programs that leverage strong human genetics and other validated targets. Marea is led by a dynamic team of scientists and company builders with deep know-how and experience in human genetics, adipocyte biology and cardiometabolic disease drug development.

(415) 766-3610

info@mareatx.com

135 Mississippi St
San Francisco, CA 94107

View Bio

Marea Therapeutics Launches with $190 Million to Accelerate a New Generation of Medicines for Cardiometabolic Diseases

Read More

Jeffrey Tong, Ph.D.
Partner, Third Rock Ventures

One of the last frontiers of cardiovascular risk: remnant cholesterol.

Precillia Redmond, MBA
Interim Head of HR

View Bio

Peter Thomson, MBA
Interim Head, Finance and Accounting

View Bio

Investors

News

Marea was founded with the ambitious goal to solve a big problem: to combine robust human genetics and a focus on adipose biology to develop novel therapies for patients at risk for heart attacks even after controlling for classical risk factors such as obesity and elevated LDL cholesterol. Marea focuses on the risk that is strongly linked to an inability to properly store excess energy safely thus leading to very high rates of atherosclerotic heart disease and diabetes. These patients can be identified by routine measurement of elevated levels of so-called remnant cholesterol – a highly atherogenic lipid particle circulating in the blood. Marea is advancing a genetically validated therapy to address the underlying adipose dysfunction which then leads to elevated remnant cholesterol and metabolic dysfunction and ultimately risk for heart attack.

Remnant cholesterol is a critical atherogenic lipid driving cardiometabolic risk in more than five million patients in the U.S. alone. Remnant cholesterol is the cholesterol carried by triglyceride-rich lipoproteins and drives risk of cardiovascular disease independent of classical risk factors like LDL cholesterol, diabetes or obesity. There are no available targeted therapies to lower remnant cholesterol.

June 18, 2024   

Marea Therapeutics Launches with $190 Million to Accelerate a New Generation of Medicines for Cardiometabolic Diseases

Read Article

Maha Katabi, Ph.D.
General partner, Sofinnova Investments

Antoine Boulanger, Ph.D.
Principal, Forbion


Aaron Royston, M.D.
Managing partner, venBio

Chris Garabedian
Venture portfolio manager, Perceptive Advisors

Caitlin Murray, Esq.
Interim Chief Legal Officer

View Bio

Ethan Weiss, M.D.
Chief Scientific Officer, Marea Therapeutics

Christine Garrett, Ph.D.
Chief Strategy Officer

View Bio

June 18, 2024  |  Endpoints   

Marea Therapeutics Launches with $190 Million to Accelerate a New Generation of Medicines for Cardiometabolic Diseases

Read Article

June 18, 2024 |  STAT     

How a tweet about a gene discovered long ago led to a $190 million startup and, maybe, hope for heart disease

Read Article

June 18, 2024  |  ENDPOINTS

Marea Therapeutics launches with $190M, seeing a 'fixable problem' in a neglected cardiometabolic target

Read Article

June 18, 2024   

Marea, Incubated by Third Rock, Gets $190M to Take Aim at Remnant Cholesterol

Read Article